KR101666838B1

KR101666838B1 - Scar treatment Systems

Info

Publication number: KR101666838B1
Application number: KR1020150066406A
Authority: KR
Inventors: 윤종인; 이형오
Original assignee: 대구가톨릭대학교산학협력단
Priority date: 2015-05-13
Filing date: 2015-05-13
Publication date: 2016-10-17

Abstract

The present invention relates to a system for treating scar on skin. To this end, the system comprises: a drug increasing cross-linking between collagen fibers after applied on a scar portion; a probe taking down ions from a negative electrode along with drugs into tissues; and a light source including a light-emitting diode (LED) and a laser diode.

Description

[0001] Scar treatment systems [

More particularly, the present invention relates to a non-invasive scar treatment system capable of achieving excellent therapeutic effect while minimizing treatment time without bleeding and pain.

Usually, a scar is a sign of healing of a damaged skin. When a deep layer of the dermis is damaged by surgery or trauma, the damaged dermis does not recover to its normal shape during the treatment of the skin. In other words, normal dermal tissue has collagen fibers randomly arranged, but scar tissue is thin and collagen fibers are arranged parallel to the epidermis. These scars are divided into atrophic scars, hypertrophic scars, and keloids. Atrophic scars are formed by depression of fat or muscle, and hypertrophic scars arise in the recovery process due to overgrowth of collagen. Kelloids are similar to hypertrophic scars, but inflammatory neoplasms are found in tissues.

Today, the importance of beauty is increasing day by day. For example, Korean Patent Registration No. 10-1397114 entitled "Composition for external application for skin for scar treatment" is disclosed. The disclosed document proposes a composition for applying a drug having a predetermined efficacy to a scar. However, when the drug is penetrated to the dermis, the effect is exerted. In fact, since the drug can not penetrate into the dermis, the treatment period is lengthened and the loss of drug is large. As another example, Korean Patent Registration No. 10-1455817 entitled " A pharmaceutical composition for treating skin scars and a skin scar treatment method using the same "is disclosed. The disclosed document suggests that a drug is injected into the dermis of the scar forcibly and then treated with scarring or laser treatment of the scar. However, people with hypersensitivity reactions to botulinum toxin components are excluded from the procedure and suffer from various side effects.

In addition, Korean Patent Registration No. 10-0820164 entitled "Laser Device for Treatment of Skin Disease ", Korean Patent Registration No. 10-1015881 entitled " System for treating scarring and skin disease using laser and method thereof, 1160343 "Photodynamic therapy apparatus and methods for burns, wounds and related skin diseases" are disclosed. The disclosed documents propose a procedure for stimulating scar tissue with light (light) emitted from a laser diode or a light emitting diode.

Here, the procedure using light sources is divided into invasive and non-invasive procedures. The invasive procedure removes the epidermis and dermis of the scar and stimulates the tissue with laser to induce the creation of new skin. This invasive procedure has the disadvantage that the light source is directly irradiated to the tissue, and thus the therapeutic effect is high, but the recovery time is long and infection, hemorrhage and secondary scarring are formed. Noninvasive procedures, on the other hand, induce collagen remodeling by stimulating the dermis with light of red and near-infrared wavelengths without damaging the scar. These non-invasive procedures have the advantage of having no bleeding and pain but comfortable treatment, but they are ineffective compared to invasive procedures, have a long treatment period and increase the cost.

Korean Patent Registration No. 10-1397114 entitled "Skin external application composition for scar treatment" Korean Patent Registration No. 10-1455817 entitled "PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SKIN SCRAMS AND METHOD FOR TREATING SKIN SCRATS USING THE SAME" Korean Patent Registration No. 10-0820164 entitled "Laser Device for Treatment of Skin Disease" Korean Patent Registration No. 10-1015881 entitled " System for treating scars and skin diseases using laser and method thereof " Korean Patent Registration No. 10-1160343 entitled " Photodynamic therapy apparatus and method for burns, wounds and related skin diseases "

Accordingly, it is an object of the present invention to fundamentally solve the above-mentioned problems of the prior art, and it is an object of the present invention to provide a method of scarifying a scar by introducing an agent capable of improving scarring into a dermis by ion transport, activating a drug penetrated into a light source, The purpose of the present invention is to provide a scar treatment system including only the advantages of the drug application procedure and the invasive operation using the light source and the noninvasive operation.

In order to achieve the above object, the present invention provides a system for treating scarring of skin comprising: heating 92 to 96% by weight of distilled water to increase cross-linking of collagen fibers applied to a scar site, then washing with benzalkonium chloride, 0.01 to 0.1% by weight of glycerin and 2 to 10% by weight of glycerin are added and stirred until completely dissolved. Subsequently, the temperature is lowered and 0.05 to 0.5% by weight of riboflavin, 0.2 to 1.0% by weight of sodium chloride, 1.0 to 5.0% by weight of Scclerotium gum at the same time, agitated to dissolve completely, and then cooled at room temperature to have a sticky viscosity; A power source of 5 to 15 V and 1 mA to 10 mA is applied to the scar of the scar so as to infiltrate the drug into the tissue by the ionic charge and a positive electrode attached to the skin 10 to 18 cm away from the scarter by a predetermined pulse, A probe that drops into the tissue together with the agent; A light emitting diode which emits a wavelength of 320 to 400 nm and 7 mW / cm 2 to activate active agent in a triplet state to produce active oxygen; and a light emitting diode which stimulates fibroblasts to form collagen fibers, And a laser diode emitting a wavelength of 100 mW / cm < 2 >.

delete

It should be understood, however, that the terminology or words of the present specification and claims should not be construed in an ordinary sense or in a dictionary, and that the inventors shall not be limited to the concept of a term It should be construed in accordance with the meaning and concept consistent with the technical idea of the present invention based on the principle that it can be properly defined. Therefore, the embodiments described in the present specification and the configurations shown in the drawings are merely the most preferred embodiments of the present invention, and not all of the technical ideas of the present invention are described. Therefore, It is to be understood that equivalents and modifications are possible.

As described in the above-mentioned constitution and operation, according to the present invention, a drug having an effect of improving scarring is infiltrated into the dermis by ion transport, the drug penetrated into the light source is activated and the tissue is stimulated, The advantages of invasive and non-invasive procedures are all provided to provide the effect of excellent bleeding and pain, minimizing the duration of treatment and achieving excellent therapeutic effects.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a block diagram generally showing a system according to the present invention; FIG.
Figures 2 to 4 illustrate a procedure for treating a scar with a system according to the present invention.

Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings.

The present invention relates to a system for improved treatment of a scar 1 according to a wound of the skin S and comprises a non-invasive scar which mainly comprises the medicament 10, the probe 20 and the light source 30 as shown in Fig. Treatment system. The system of the present invention overcomes the disadvantages of the existing procedure and has merits merely so as to provide excellent therapeutic effect while minimizing the bleeding and pain and minimizing the treatment period.

The medicament 10 according to the present invention is applied to the area of the scar 1 as shown in FIG. 2 to increase the crosslinking of collagen fibers. Such a medicament 10 may contain 0.05 to 0.5% by weight of riboflavin, 0.2 to 1.0% by weight of sodium chloride, 0.01 to 0.1% by weight of benzalkonium chloride, 2 to 10% by weight of distilled water, By weight of glycerin, and 1.0 to 5.0% by weight of sclerotium gum.

Riboflavin is a vitamin B2 substance that is water-soluble and has heat-stable properties. And plays an important role in the metabolism of body energy and participates in the essential metabolic process to supply energy necessary for the assimilation process of wound healing. When riboflavin is irradiated with light in the UV-A band (320-400 nm), active oxygen is generated, thereby forming a new covalent bond between the collagen fibers, thereby increasing crosslinking of collagen fibers.

Here, since riboflavin is a liquid, it flows down at the time of application, and therefore it is required to have a viscosity capable of staying in the scar (1) while having an osmotic pressure capable of penetrating to the dermis. That is, sodium chloride and benzalkonium chloride improve the penetration by changing the osmotic concentration of riboflavin, and glycerin changes the refractive index of light to help penetrate into the skin (S). Finally, the sclerotium gun changes to a creamy viscous so that it can stay in the scar (1).

3, the probe 20 according to the present invention forcibly infiltrates the drug 10 applied to the scar 1 into the tissue by ionic charge. The probe 20 is applied to the scar 1 and a positive electrode 25 attached to the skin S spaced 10 to 18 cm from the negative electrode 21 by a voltage of 5 to 15 V and a power of 1 mA to 10 mA Is applied with a predetermined pulse to drop ions of the cathode electrode 21 together with the agent 10 into the tissue.

That is, the drug 10 is actively transported to the dermis using a small electric charge. Here, DC power supply may be continuously applied, but since the ion transport efficiency decreases, it is preferable to apply the pulse current. It is preferable to apply a liquid phase that can be energized with the medicine 10 before the positive electrode 25 is attached to the skin S.

In addition, the light source 30 according to the present invention activates the medicament 10 penetrated into the tissue of the scar 1 as a triplet state and stimulates fibroblasts as shown in FIG. The light source 30 includes a light emitting diode 31 that emits a wavelength of 320 to 400 nm and 7 mW / cm 2 to activate the drug 10 in triplicate to generate active oxygen, and a light emitting diode 31 that stimulates fibroblasts to generate collagen fibers And a laser diode 35 which emits a wavelength of 620 to 640 nm and 100 mW / cm 2 for reformation.

The light emitting diode 31 irradiates the scar 1 with light to activate the penetrated medicament 10. That is, when the medicine 10 starts to absorb light, it is excited into a triplet state and immediately generates active oxygen. The activated oxygen generated here forms a new covalent bond between the collagen fibers, thereby increasing collagen crosslinking. The laser diode 35 removes the scar fibroblasts and regenerates the collagen fibers through normal fibroblast stimulation and alleviates the itching, pigmentation and pain of the scar (1).

Hereinafter, a specific treatment example according to the system of the present invention will be examined to see if the practical effect of scar treatment is effective.

<< How to treat >>

The pig skin, which is known to be the most similar to human skin, was treated with non - treatment, light therapy, medication, light source + medicine treatment group and then examined collagen fiber of dermis by electron microscope. Prior to this, in order to verify the penetration of the drug by the probe, 10 V, 5 mA, 2.5 mA, and 0 mA power were applied to the skin, and the skin was visually inspected.

&Lt; Preparation of pharmaceutical &

After heating 9.49 ml of distilled water, 0.01 ml of benzalkonium chloride and 0.5 ml of glycerin were added and stirred until completely dissolved. Subsequently, when the benzalkonium chloride and glycerin were completely dissolved, the temperature was lowered, 10 mg of riboflavin, 44 mg of sodium chloride and 200 mg of Scclerotium gum were simultaneously added, and stirred until they were completely dissolved gave. Then, the solution was cooled at room temperature to complete a drug having sticky viscosity.

First, the finished skin was applied to the skin of pigs, and then power was applied for 10 minutes by the following apparatus.

- Probe unit -

Then, after removing the pig skin from the device, the plane and cross section of the skin were photographed with a digital camera as follows.

10mA 5mA 2.5 mA 0 mA

- Flat pictures -

10mA 5mA 2.5 mA 0 mA

- Simplex picture -

As a result of the verification, it was confirmed that the drug of pig skin to which the electric current was applied had a significantly high infiltration amount. The larger the current intensity, the higher the penetration rate of the drug.

First, four pig skin cut into 2 cm x 3 cm sized pieces were prepared and then the same amount of the medicament was applied. Then, a power of 10 V and 10 mA was applied for 10 minutes to infiltrate the drug. Then, non-treatment, light source treatment, medication treatment, light source + medication treatment were performed simultaneously at the same time. As a light source, a light emitting diode emitting a wavelength of 375 nm and 7 mW / cm 2 and a laser diode emitting a wavelength of 635 nm and 100 mW / cm 2 were irradiated for 20 minutes.

Non-treatment Light source treatment Medication Light source + medicine treatment

&Lt; Treatment result >

As a result of treatment, Group A, which is a non-treated group, had dermal dermal collagen fibers arranged horizontally on the surface. In Group B, which treated only the light source, fiber thickness was thicker and randomized. Group C, And there is no difference in directionality. However, group D, which treated both light source and medication, increased fiber density, increased in thickness, and arranged in a random direction.

When the light source or the medicament alone is treated as such, the effect is insignificant. However, it can be seen that when the light source and the medicament are applied together as in the system of the present invention, there is an excellent effect of treating the scar.

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit and scope of the invention as defined by the appended claims. It is therefore intended that such variations and modifications fall within the scope of the appended claims.

S: Skin 1: Scar
10: drug 20: probe
21: negative electrode 25: positive electrode
30: light source 31: light emitting diode
35: Laser diode

Claims

A system for treating skin scarring comprising:
92 to 96% by weight of distilled water is heated so as to increase crosslinking of the collagen fibers, 0.01 to 0.1% by weight of benzalkonium chloride and 2 to 10% by weight of glycerin are added After stirring, the temperature was lowered and 0.05 to 0.5% by weight of Riboflavin, 0.2 to 1.0% by weight of sodium chloride and 1.0 to 5.0% by weight of Scclerotium gum were simultaneously added thereto A drug having a sticky viscosity which is stirred at room temperature after stirring until completely dissolved;
A power source of 5 to 15 V and 1 mA to 10 mA is applied to the scar of the scar so as to infiltrate the drug into the tissue by the ionic charge and a positive electrode attached to the skin 10 to 18 cm away from the scarter by a predetermined pulse, A probe that drops into the tissue together with the agent; And
A light emitting diode which emits a wavelength of 320 to 400 nm and 7 mW / cm 2 so as to generate active oxygen by activating the drug in a triplet state, and a light emitting diode which emits light of 620 to 640 nm And a laser diode emitting a wavelength of 100 mW / cm < 2 >.

delete